Cagrilintide

Cagrilintide is a long-acting, synthetic analogue of the natural hormone amylin, which is co-secreted with insulin by the pancreatic beta cells. It functions as a non-selective amylin receptor agonist and also activates calcitonin receptors, making it a potent regulator of metabolic function. Its primary research application lies in its profound impact on appetite suppression and weight management. By mimicking the effects of amylin, Cagrilintide signals the brain to induce a feeling of early satiety (fullness) and significantly slows gastric emptying. This results in a substantial reduction in caloric intake and body weight, placing it at the forefront of next-generation obesity research.

Beyond its role as a standalone compound, Cagrilintide is particularly noted for its synergistic potential when studied alongside GLP-1 receptor agonists. Research indicates that targeting both the amylin and GLP-1 pathways can lead to more significant improvements in glycemic control and fat loss than single-target therapies. This dual-pathway approach is believed to help the body maintain a lower “set point” for weight. Furthermore, Cagrilintide is being explored for its effects on glucose homeostasis and lipid metabolism. As a highly purified peptide, it provides researchers with essential insights into how amylin-based therapies can be optimized to treat chronic metabolic disorders and obesity-related health issues.